Posaconazole: An Update of Its Clinical Use.

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• Posaconazole (PCZ) is an extended-spectrum triazole antifungal agent.
• It exhibits fungicidal and fungistatic activity against a wide range of fungal pathogens, including Aspergillus, Candida, Cryptococcus, and Zygomycetes.
• Synergistic interactions observed when combined with caspofungin or amphotericin B.

Purpose of the Study:

• To review the pharmacological properties, spectrum of activity, and clinical applications of posaconazole.
• To highlight the expanded therapeutic options with new formulations.
• To emphasize the importance of monitoring drug-drug interactions due to CYP3A4 inhibition.

Main Methods:

• Review of existing literature on posaconazole's efficacy and pharmacokinetics.
• Analysis of its spectrum of activity against key fungal pathogens.
• Evaluation of absorption, distribution, metabolism, and excretion (ADME) properties.

Main Results:

• Posaconazole demonstrates broad-spectrum antifungal activity.
• Absorption is enhanced with food or specific beverages; divided oral doses increase bioavailability.
• High protein binding (>95%) and fecal elimination are characteristic; CYP3A4 inhibition necessitates interaction monitoring.

Conclusions:

• Posaconazole is a valuable antifungal agent, expanding the azole class.
• Newer formulations (delayed-release tablets, IV) have broadened its clinical utility, especially for immunocompromised patients.
• Careful consideration of drug interactions and administration guidelines is crucial for optimal outcomes.